Mirae Asset Global Investments
ELVN icon

Mirae Asset Global Investments’s Enliven Therapeutics ELVN Stock Holding History

Mirae Asset Global Investments’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138K Sell
2,724
-372
-12% -$15.8K ﹤0.01% 1179
2026
Q1 		$121K Buy
3,096
+212
+7% +$5.87K ﹤0.01% 1150
2025
Q4 		$44.4K Buy
2,884
+594
+26% +$11.8K ﹤0.01% 1420
2025
Q3 		$46.9K Buy
2,290
+394
+21% +$7.94K ﹤0.01% 1357
2025
Q2 		$38K Buy
1,896
+261
+16% +$4.94K ﹤0.01% 1300
2025
Q1 		$34.4K Buy
1,635
+7
+0.4% +$151 ﹤0.01% 1308
2024
Q4 		$36.4K Sell
1,628
-80
-5% -$2.07K ﹤0.01% 1319
2024
Q3 		$41.2K Buy
1,708
+304
+22% +$7.04K ﹤0.01% 1336
2024
Q2 		$32.9K Buy
+1,404
New +$29.6K ﹤0.01% 1316
2024
Q1 		– Sell
-12,305
Closed -$170K – 2491
2023
Q4 		$170K Buy
12,305
+1,029
+9% +$12.6K ﹤0.01% 2368
2023
Q3 		$154K Hold
11,276
– – ﹤0.01% 2365
2023
Q2 		$230K Buy
+11,276
New +$228K ﹤0.01% 2289

Other funds holding ELVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Mirae Asset Global Investments's ELVN Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Enliven Therapeutics (ELVN) stake by 12% in Q2 2026, selling an estimated $15.8K and leaving 2,724 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #1179.

Mirae Asset Global Investments first reported a position in ELVN in Q2 2023 and has held it in 12 quarters since. The position peaked at $230K in Q2 2023. 49 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Mirae Asset Global Investments held 2,724 shares of Enliven Therapeutics worth $138K as of Q2 2026.
  • Mirae Asset Global Investments sold 372 Enliven Therapeutics shares in Q2 2026, an estimated $15.8K.
  • Enliven Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1179 holding.
  • Mirae Asset Global Investments first reported a position in Enliven Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Mirae Asset Global Investments's Enliven Therapeutics position peaked at $230K in Q2 2023.
  • 49 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.